(Q34953360)

5 August 2017

1 reference

title

Quality of life in patients undergoing systemic therapy for advanced breast cancer (English)

1 reference

5 August 2017

1 reference

1 reference

1 reference

1

Andrew Bottomley

1 reference

5 August 2017

Patrick Therasse

2

1 reference

5 August 2017

publication date

1 October 2002

1 reference

Lancet Oncology Commission

5 August 2017

published in

1 reference

5 August 2017

volume

3

1 reference

5 August 2017

issue

10

1 reference

5 August 2017

page(s)

620-628

1 reference

The problem of quality of life in medicine

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Guidelines for reporting results of quality of life assessments in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Quality of life assessment in daily clinical oncology practice: a feasibility study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Endpoints in cancer clinical trials: is there a need for measuring quality of life?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

What are quality of life measurements measuring?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Reporting on quality of life in randomised controlled trials: bibliographic study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Collecting quality of life data in EORTC clinical trials--what happens in practice?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Quality of life instruments in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Quality of life in women with recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Methodological issues in the assessment of health-related quality of life in palliative care trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Breast conservation versus mastectomy: distress sequelae as a function of choice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Quality of life in the first year after breast cancer surgery: rehabilitation needs and patterns of recovery.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Surgical options for the early-stage breast cancer: factors associated with patient choice and postoperative quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Evaluation of quality of life in patients receiving treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

Quality of life in breast cancer patients: measurement issues in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900876-8

7 January 2021

10.1016/S1470-2045(02)00876-8

Identifiers

DOI

1 reference

5 August 2017

1 reference